Antisera to Detect Phosphorylated Phosphoinositide-Dependent Kinase 1 (PDK-
Background:
The National Institutes of
Health, National Center for Complementary and Alternative Medicine,
Diabetes Unit is seeking statements of capability or interest from
parties interested in collaborative research to further develop,
evaluate, or commercialize phospho-specific PDK-1 antibody and
insulin signaling.
Technology:
PDK-1 phosphorylates and
activates a number of cellular kinases and plays a major role in
insulin and growth factor signaling. PDK-1 also represents a
promising drug target for a number of cancers. Autophosphorylation
at Ser244 (mouse) or Ser241 (human) is critical for PDK-1
activity.
Available for licensing are polyclonal rabbit antisera that
specifically detect mouse PDK-1 protein phosphorylated at Ser244.
These antisera are also expected to be specific for the human PDK-1
protein phosphorylated at Ser241.
IP Status:
Research
Tool
Value
Proposition--Solution:
- Tool for screening PDK-1 autophosphorylation inhibitors for
cancer and other indications
- Tool for studying insulin and growth factor signaling
Contact
Information:
John D. Hewes, Ph.D., NCI
Technology Transfer Center
Phone: 301-435-3121
E-mail: Hewesj@mail.nih.gov
Reference: #580 CM
Posted 11/21/2007
This opportunity is also listed under the following categories: